SB 939
Relating to testing for substance use disorder
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House of Delegates
- To Governor
- Became Law
Bill overview
This bill establishes guidelines for drug testing within office-based medication-assisted treatment programs in West Virginia. It requires patients admitted to these programs to undergo initial and ongoing quantitative drug tests, transitioning to qualitative tests during stabilization and maintenance phases. Providers can request additional tests to assess patient compliance. The goal is to monitor patient progress and adherence to treatment plans.
Key provisions
- Requires initial quantitative drug test upon admission to an office-based medication-assisted treatment program.
- Mandates direct observation drug tests every two weeks for six weeks following the initial test.
- Specifies qualitative drug tests every 45 days for one year during the stabilization phase.
- Requires qualitative drug tests every six months during the maintenance phase.
- Allows providers to request additional tests for compliance assessment.
- Patients must consent to provide tests upon request.
Who is affected
- Patients receiving medication-assisted treatment
- Office-based medication-assisted treatment facilities
- Providers of medication-assisted treatment
Notable changes
- Establishes a schedule of drug testing requirements for patients in medication-assisted treatment programs.
- Defines the types of tests (quantitative and qualitative) and their frequency.
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yours